How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Transfusion Diagnostic Equipments Market
- By Product Type: Blood Grouping Systems, Antibody Screening Systems, Crossmatching Systems, Coagulation Analyzers, Blood Component Analyzers
- By Technology: Gel Card Technology, Microplate Technology, Column Agglutination Technology, Solid Phase Technology, Flow Cytometry
- By End User: Hospitals, Diagnostic Laboratories, Blood Banks, Research Institutes, Specialty Clinics
- By Application: Blood Typing, Antibody Detection, Compatibility Testing, Coagulation Testing, Quality Control
- By Automation Level: Manual Systems, Semi-Automated Systems, Fully Automated Systems
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Blood Grouping Systems leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the Transfusion Diagnostic Equipments Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Technology 5
End User 5
Application 5
Automation Level 3
Companies profiled
Grifols S.A.
Terumo Corporation
Haemonetics Corporation
Fresenius Kabi AG
Macopharma
Ortho Clinical Diagnostics (a part of Ortho Clinical Diagnostics Holdings)
Sartorius AG
Becton
Dickinson and Company (BD)
Bio-Rad Laboratories Inc.
Danaher Corporation (including Beckman Coulter)
Siemens Healthineers
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Grifols S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Haemonetics Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Fresenius Kabi AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Macopharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Ortho Clinical Diagnostics (a part of Ortho Clinical Diagnostics Holdings)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Bio-Rad Laboratories Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Danaher Corporation (including Beckman Coulter)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Siemens Healthineers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Abbott Laboratories
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Sysmex Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Helena Laboratories
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Ortho Clinical Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →
Global · 2025–2033
$1,103M by 2033 · 4.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Blood Grouping Systems33.4
- Antibody Screening Systems14.4
- Crossmatching Systems15.4
- Coagulation Analyzers18.4
- Blood Component Analyzers18.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$264.4M → $325.0M · 2.6%
Europe$184.2M → $275.5M · 5.2%
Asia Pacific$168.2M → $261.6M · 5.7%
Latin America$104.1M → $136.0M · 3.4%
Middle East and Africa$80.1M → $118.1M · 5.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.032026
4.052027
4.062028
4.072029
4.072030
4.092031
4.102032
4.132033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Grifols S.A.18.7
- Terumo Corporation17.2
- Haemonetics Corporation5.3
- Fresenius Kabi AG7.0
- Macopharma11.9
- Ortho Clinical Diagnostics (a part of Ortho Clinical Diagnostics Holdings)11.9
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type19.6%
Technology22.9%
End User24.1%
Application21.2%
Automation Level12.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.1
- Europe24.7
- Asia Pacific23.4
- Latin America12.2
- Middle East and Africa10.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Grifols S.A. | 80 | 73 | 84 | 94 | 76 | 93 | 83 |
| Terumo Corporation | 87 | 80 | 87 | 70 | 72 | 85 | 80 |
| Haemonetics Corporation | 84 | 69 | 88 | 71 | 87 | 80 | 80 |
| Fresenius Kabi AG | 76 | 58 | 62 | 76 | 61 | 81 | 69 |
| Macopharma | 54 | 66 | 59 | 66 | 59 | 62 | 61 |
| Ortho Clinical Diagnostics (a part of Ortho Clinical Diagnostics Holdings) | 69 | 56 | 71 | 52 | 66 | 58 | 62 |
| Sartorius AG | 61 | 54 | 52 | 61 | 55 | 56 | 57 |
| Becton | 40 | 53 | 40 | 53 | 36 | 47 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Grifols S.A.
- Terumo Corporation
- Haemonetics Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Grifols S.A. | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Terumo Corporation | ◐ | ◐ | ✓ | − | ◐ | ✓ |
| Haemonetics Corporation | ✓ | ✓ | ✓ | ◐ | ◐ | ◐ |
| Fresenius Kabi AG | ✓ | − | − | ◐ | − | ✓ |
| Macopharma | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Ortho Clinical Diagnostics (a part of Ortho Clinical Diagnostics Holdings) | − | ◐ | ◐ | − | ✓ | ◐ |
| Sartorius AG | ◐ | ◐ | − | − | ◐ | ◐ |
| Becton | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Grifols S.A.83
2Terumo Corporation80
3Haemonetics Corporation80
4Fresenius Kabi AG69
5Ortho Clinical Diagnostics (a part of Ortho Clinical Diagnostics Holdings)62
6Macopharma61
7Sartorius AG57
8Becton45
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Grifols S.A.Terumo CorporationHaemonetics Corporation
Challenger1
Strong scale, closing on the leaders.
Fresenius Kabi AG
Contender3
Focused players with pockets of strength.
MacopharmaOrtho Clinical Diagnostics (a part of Ortho Clinical Diagnostics Holdings)Sartorius AG
Niche1
Specialists in a single segment or region.
Becton
Go-to-market strategy
Land Product Type in North America, then scale across Transfusion Diagnostic Equipments Market — a $211M beachhead inside a $3.03B market.
Beachhead (SOM)$211Mobtainable near-term
Serviceable (SAM)$1.26Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Blood Grouping Systems
Best fit — highest urgency & budget in Product Type.
Economic buyer76 fit
Antibody Screening Systems
Strong fit — clear ROI and a fast path to value.
End user69 fit
Crossmatching Systems
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel25%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Transfusion Diagnostic Equipments Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified24%
Evaluation15%
Closed-won6%
$17.4KCAC
$100KLTV
5.7:1LTV : CAC
< 3 moCAC payback
Investment thesis
Transfusion Diagnostic Equipments Market is a resilient opportunity — $5.79B by 2033, compounding at 5.1%.
TAM · 2025$3.87Btoday
TAM · 2033$5.79Bforecast
CAGR5.1%2027–2033
Cumulative$43.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.79BTotal addressable market
SAM$2.01BServiceable available market
SOM$438MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.1% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.79BLarge & growingTAM by 2033 at 5.1% CAGR
$2.01BServiceable nowreachable with today’s model
$438MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.51BBear3.3% CAGR
$5.79BBase5.1% CAGR
$7.41BBull6.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Transfusion Diagnostic Equipments Market — a $7.68B market by 2033. Plan: grow share from 5.9% to 11.5%.
Market size · 2033$7.68Btotal addressable
Market CAGR5.6%2027–2033
Target share11.5%from 5.9% today
Revenue ambition$884Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.9% | 11.5% | On track |
| Revenue | $452M | $884M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.0% | 38.6% | On track |
| Customer retention | 90.0% | 92.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $130M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentBehind
Sales deck · value proposition
Win the Transfusion Diagnostic Equipments Market conversation — a $7.28B market you can size, segment and defend in minutes.
Market size · 2033$7.28Btotal opportunity
Growth9.6%CAGR to 2033
Addressable buyers1,081+accounts in scope
Typical ROI6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6×return on cost, year one
< 3 mopayback period
$74K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Grifols S.A.Terumo CorporationHaemonetics CorporationFresenius Kabi AGMacopharmaOrtho Clinical Diagnostics (a part of Ortho Clinical Diagnostics Holdings)Sartorius AGBecton+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Transfusion Diagnostic Equipments Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Transfusion Diagnostic Equipments Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Pulmonary Arterial Hypertension Drugs Market
Market size, share, segmentation and regional forecast.
$3.6B by 2032 · 8.55% CAGR
View reportPulmonary Drugs Market
Market size, share, segmentation and regional forecast.
$3.0B by 2033 · 8.71% CAGR
View reportNuclear Medicine Equipments Market
Market size, share, segmentation and regional forecast.
$12.6B by 2032 · 10.35% CAGR
View reportLiposome Drug Delivery Market
Market size, share, segmentation and regional forecast.
$7.1B by 2033 · 4.36% CAGR
View reportObstructive Sleep Apnea Therapeutic Device Market
Market size, share, segmentation and regional forecast.
$2.0B by 2031 · 10.63% CAGR
View reportOral Vaccine Market
Market size, share, segmentation and regional forecast.
$14.4B by 2031 · 9.14% CAGR
View reportPolypectomy Snare Market
Market size, share, segmentation and regional forecast.
$9.1B by 2032 · 8.17% CAGR
View reportCoextruded Medical Tube Market
Market size, share, segmentation and regional forecast.
$9.6B by 2033 · 8.60% CAGR
View reportCoronary Guidewire Market
Market size, share, segmentation and regional forecast.
$672M by 2033 · 6.05% CAGR
View reportLight Sources For Endoscope Market
Market size, share, segmentation and regional forecast.
$14.3B by 2033 · 8.79% CAGR
View reportOphthalmic Diagnostic Device Market
Market size, share, segmentation and regional forecast.
$12.2B by 2031 · 4.49% CAGR
View reportOphthalmic Operating Microscope Market
Market size, share, segmentation and regional forecast.
$2.1B by 2031 · 5.80% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.